Cancer Stem Cell Specific TCR-T Design & Validation Service
Creative Biolabs provides a comprehensive infrastructure to transform elusive cancer stem cells (CSCs) into viable targets by focusing on the intracellular proteome. We bypass cell-surface limitations by identifying stemness-critical peptides presented on human leukocyte antigen (HLA) molecules and engineering T-cell receptors (TCRs) with optimal affinity to destroy quiescent cells. Our approach validates candidates in high-fidelity 3D tumor spheroids and patient-derived organoids, ensuring high potency despite the hypoxic, immunosuppressive niche, effectively preventing tumor escape and metastatic relapse.
The Science of Targeting the Roots of Malignancy with TCR-T
CSCs represent the primary barrier to permanent tumor eradication due to their quiescence and major histocompatibility complex (MHC)-dependent presentation of intracellular antigens. Unlike bulk tumor cells, CSCs often lack high-density surface markers, rendering conventional therapies ineffective. Recent research has confirmed that TCR-T therapies, particularly those optimized via AI-generative models and structural engineering, offer the sensitivity required to detect low-density CSC epitopes. By integrating these high-end technologies, Creative Biolabs provides a credible, evidence-based pathway to eliminate the root cause of malignancy and prevent metastatic relapse.
Comprehensive Deliverables for CSC-Targeted TCR-T Development
Our service suite is meticulously structured to cover the entire developmental arc of a CSC-targeted immunotherapy:
Precision Immunopeptidomics
Utilizing high-resolution mass spectrometry to map the "CSC-specific" ligandome, identifying unique targets that are exclusive to the stem cell compartment.
Generative TCR Design
Leveraging our proprietary AI-driven platform to design functional TCR sequences against novel or "unseen" epitopes, significantly expanding the targetable landscape beyond known antigens.
Functional Proliferation Screening
Employing CFSE-based assays to isolate the most reactive TCR clones based on actual functional activation and expansion.
Safety & Structural Engineering
Implementing cysteine modifications and murinization of constant regions to enhance TCR stability and prevent dangerous mispairing with endogenous TCRs.
High-Fidelity Validation
Providing rigorous potency data through patient-derived organoids-based killing assays and in vivo xenograft studies (CDX/PDX) to support regulatory submissions.
Explore How Our Customized Platforms Can Accelerate Your Pipeline - Inquire About Our Specialized Offerings
Workflow
Creative Biolabs has developed a streamlined "design-to-validation" workflow that minimizes experimental risk while maximizing the functional potency of your TCR-T candidates.
Publication
This review summarizes the identification, design, and clinical application of tumor-specific neoantigens for TCR-T cell therapy. It explores how advances in next-generation sequencing and bioinformatics enable the prediction of personalized neoantigens, which serve as ideal targets for immunotherapy due to their high tumor specificity and immunogenicity. The article also discusses current challenges, such as neoantigen prediction accuracy, immune evasion, and therapy safety, and highlights the promising clinical translation potential of TCR-T-based strategies in treating various cancers.
Fig.1 Accelerated discovery of neoantigen-specific TCRs for tailored TCR-T cell therapies. 1
Why Choose Us?
Choosing Creative Biolabs means partnering with a global leader in immunotherapy that seamlessly bridges the gap between stem cell biology and advanced TCR engineering. With over two decades of technical expertise, we have optimized our platforms to navigate the specific complexities of the MHC-peptide interaction within the immunosuppressive cancer stem cell niche. Our unique advantage lies in our generative AI-driven TCR discovery platform, which can design high-affinity receptors for "unseen" CSC epitopes where traditional data is sparse. By leveraging published data and proprietary structural optimization, we ensure your candidates exhibit superior potency and a rigorous safety profile, drastically reducing your lead optimization timelines.
Leverage Our Two Decades of Immunotherapy Expertise - Experience the Creative Biolabs Advantage Today
FAQs
What makes TCR-T better than CAR-T for cancer stem cells?
Many critical CSC markers are transcription factors located inside the cell. TCR-T can see these internal fragments via MHC molecules, whereas CAR-T is limited to the cell surface.
How do you prevent the engineered TCR from mispairing with the T-cell's own TCR?
We implement cysteine modifications and murinization of constant regions to ensure the engineered alpha/beta chains pair only with each other, maximizing safety and efficacy.
Can you target CSCs if the antigen density is very low?
Yes. TCRs are evolutionarily optimized to trigger cell killing with as few as 1–10 pMHC complexes, making them ideal for the "stealthy" CSC phenotype.
Customer Review
-
Exceptional Specificity
Using Creative Biolabs' TCR-T design in our research has significantly facilitated the targeting of rare CD44+ subpopulations that were previously invisible to our CAR-T constructs. The specificity against intracellular markers is a game-changer. - Dr. Elena V** -
Robust Validation
The inclusion of patient-derived organoids in the validation phase helped us identify potential escape mechanisms early. Their CFSE-based screening is far more reliable than traditional tetramer staining for functional lead selection. - Prof. Mark Sc**
Related Services
Patient Derived Organoid Models
Creative Biolabs provides patient-derived organoids models for disease modeling and high-throughput drug screening. Our biobank captures genetic diversity, improving clinical decision-making and precision cancer treatment.
Learn More →Antibody and Protein Pharmacology
Creative Biolabs provides pharmacology solutions and custom cancer animal models. We offer pharmacokinetics, toxicology, and safety studies to ensure robust preclinical drug characterization.
Learn More →How to Contact Creative Biolabs
Creative Biolabs offers the industry's most comprehensive suite for cancer stem cell specific TCR-T design and validation. From AI-driven sequence generation to high-fidelity organoid testing, we provide the expertise needed to eradicate the root of cancer.
For detailed technical information or to discuss your specific project requirements, please contact our expert scientific team. We are ready to help you accelerate your immunotherapy pipeline.
Reference
- Li, Jiangping, et al. "The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells." Molecular Cancer 22.1 (2023): 141. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1186/s12943-023-01844-5
Download our brochure